Gangliosides as Therapeutic Targets for Neurodegenerative Diseases.
Journal
Journal of lipids
ISSN: 2090-3030
Titre abrégé: J Lipids
Pays: Egypt
ID NLM: 101553819
Informations de publication
Date de publication:
2024
2024
Historique:
received:
28
09
2023
revised:
05
02
2024
accepted:
22
03
2024
medline:
16
4
2024
pubmed:
16
4
2024
entrez:
16
4
2024
Statut:
epublish
Résumé
Gangliosides, sialic acid-containing glycosphingolipids, are abundant in cell membranes and primarily involved in controlling cell signaling and cell communication. The altered ganglioside pattern has been demonstrated in several neurodegenerative diseases, characterized during early-onset or infancy, emphasizing the significance of gangliosides in the brain. Enzymes required for the biosynthesis of gangliosides are linked to several devastating neurological disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), hereditary spastic paraplegia (HSP). In this review, we summarized not only the critical roles of biosynthetic enzymes and their inhibitors in ganglioside metabolism but also the efficacy of treatment strategies of ganglioside to address their significance in those diseases.
Identifiants
pubmed: 38623278
doi: 10.1155/2024/4530255
pmc: PMC11018381
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
4530255Informations de copyright
Copyright © 2024 Orhan Kerim Inci et al.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.